The pathogenic relevance of type I IFN system was explored clinically as anifrolumab, a type I IFN receptor antagonist, substantially reduced disease activity in patients with moderate to severe SLE, with a greater effect in those with high IFN signature at baseline [36]. The gene discussed is IFNA1; the disease is systemic lupus erythematosus.